This case study illustrates a patient with underlying LAM and TSC who developed acute hypoxemic respiratory failure secondary to COVID-19. While the literature on patients with LAM and COVID-19 is limited, recommendations should be based on guideline-directed therapy for COVID-19, and management of mTOR inhibitors should be made on an individual basis. Here, MTOR is linked to lymphangioleiomyomatosis.